Introduction - Cortical blindness, a rare form of cyclosporine (CSA) n
eurotoxicity, has previously been described in only nine bone marrow t
ransplant (BMT) recipients. Methods - Our institution averages 35 allo
geneic BMT's per year. In the past year we have seen two women with re
versible cortical blindness secondary to CSA toxicity. Results - Age (
years) (Case 1; Case 2): 32; 22. Day post-BMT: 41; 50. Peak CSA level
(ng/ml): 1159; 632. Both had a history of renal toxicity requiring adj
ustment of CSA dosage. MRI - both with diffuse white matter changes. E
EG - both with moderate to severe generalized slowing. Visual evoked p
otentials were markedly prolonged in both. Auditory evoked potentials:
minimally abnormal; normal. Somatosensory evoked potentials - both no
rmal. Prompt improvement occurred with discontinuation of CSA. Followu
p neurophysiologic evaluations were normal, however structural changes
remained on MRI. Conclusion - As neurophysiologic studies closely fol
low the clinical status they should be included in the evaluation and
followup of CSA neurotoxicity.